Search Within

Population Sciences Research Program

  1. "Elsevier Science, Inc."
Formats
  1. Journal Article (550)
  2. Meeting Abstract (171)
  3. Editorial (34)
  4. Correspondence (26)
  5. Review (13)
  6. Research Letter (11)
  7. Guidelines (9)
  8. Conference Paper (2)
Groups
  1. Epidemiology and Biostatistics (485)
  2. Surgery (410)
  3. Health Outcomes Research Group (350)
  4. Urology (260)
  5. Survivorship Research (235)
  6. Department of Medicine (219)

More Groups

People
  1. Andrew Vickers (223)
  2. T Peter Kingham (120)
  3. William Jarnagin (91)
  4. Michael D'Angelica (88)
  5. Hans Lilja (77)
  6. James Eastham (62)

More People

Years
  1. 2025 (14)
  2. 2024 (60)
  3. 2023 (43)
  4. 2022 (56)
  5. 2021 (39)
  6. 2020 (53)

More Years

Publications
  1. European Urology (178)
  2. Journal of Urology (122)
  3. Journal of Investigative Dermatology (80)
  4. Journal of the American College of Surgeons (63)
  5. Lancet Oncology (48)
  6. Urology (47)

More Publications

Publishers
  1. Elsevier Science, Inc. (816)

Results (816)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ACR Appropriateness Criteria® Imaging of Ductal Carcinoma in Situ (DCIS)
    Guidelines

    Kuzmiak, C. M.; Sharpe, R. E. Jr; Lewin, A. A.; Weinstein, S. P.; Blinder, V.; Dibble, E. H.; Dodelzon, K.; Dogan, B. E.; Paulis, L. V.; Plichta, J. K.; more...
    Journal of the American College of Radiology (2025)

    Fulltext@MSK | Save
  • Perioperative complications and omission of ureteral stents during robot-assisted radical cystectomy with intracorporeal ileal conduit
    Journal Article

    Tallman, J. E.; Vertosick, E. A.; Alam, S. M.; Baky, F. J.; Donat, S. M.; Pietzak, E. J.; Cha, E. K.; Donahue, T. F.; Bochner, B. H.; Vickers, A. J.; more...
    Journal of Urology (2025)

    Fulltext@MSK | Save
  • How to write a response to reviewers
    Editorial

    Vickers, A. J.; Assel, M.; Dunn, R. L.; MacLennan, G.; Walz, J.; Gratzke, C.; Rouprêt, M.; Briganti, A.
    European Urology (2025)

    Fulltext@MSK | Save
  • Reply by authors
    Correspondence

    Tallman, J. E.; Vertosick, E. A.; Alam, S. M.; Baky, F. J.; Donat, S. M.; Pietzak, E. J.; Cha, E. K.; Donahue, T. F.; Bochner, B. H.; Vickers, A. J.; more...
    Journal of Urology (2025)

    Fulltext@MSK | Save
  • Re: Early prostate cancer deaths among men with higher vs lower genetic risk
    Editorial

    Carlsson, S. V.; Lilja, H.; Vickers, A. J.; Bjartell, A. S.
    European Urology (2025)

    Fulltext@MSK | Save
  • Psychosocial impact associated with a multicancer early detection test (PATHFINDER): A prospective, multicentre, cohort study
    Journal Article

    Nadauld, L.; McDonnell, C. H. 3rd; Dilaveri, C. A.; Klein, E. A.; Reid, R.; Marinac, C. R.; Chung, K. C.; Lopatin, M.; Fung, E. T.; Schrag, D.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: Recommendations from the International Society of Geriatric Oncology (SIOG)
    Review

    Eochagain, C. M.; Neuendorff, N. R.; Gente, K.; Leipe, J.; Verhaert, M.; Sam, C.; de Glas, N.; Kadambi, S.; Canin, B.; Gomes, F.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Under-representation for female pelvis cancers in commercial auto-segmentation solutions and open-source imaging datasets
    Journal Article

    Thor, M.; Williams, V.; Hajj, C.; Cervino, L.; Veeraraghavan, H.; Elguindi, S.; Tyagi, N.; Shukla-Dave, A.; Moran, J. M.
    Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study
    Journal Article

    Iyer, S. P.; Sica, R. A.; Ho, P. J.; Prica, A.; Zain, J.; Foss, F. M.; Hu, B.; Beitinjaneh, A.; Weng, W. K.; Kim, Y. H.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Reevaluating the definition of clinically significant prostate cancer as grade groups 2 to 5: An imperative for improved risk stratification
    Editorial

    Carlsson, S. V.; Carroll, P. R.; Hamdy, F. C.
    Journal of Urology (2025)

    Fulltext@MSK | Save